# Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults With PKP2 Mutation-associated ARVC

> **NCT06228924** · PHASE1 · RECRUITING · sponsor: **Tenaya Therapeutics** · enrollment: 15 (estimated)

## Conditions studied

- Arrhythmogenic Right Ventricular Cardiomyopathy

## Interventions

- **GENETIC:** TN-401

## Key facts

- **NCT ID:** NCT06228924
- **Lead sponsor:** Tenaya Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-26
- **Primary completion:** 2026-05-01
- **Final completion:** 2029-10-01
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2025-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06228924

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06228924, "Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults With PKP2 Mutation-associated ARVC". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06228924. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*